|NIDDK||LBC/Section on Carbohydratesemail@example.com||3014352036||Synthetic Chemistry|
Aileen Bongat obtained her M.Sc. and Ph.D. degree in Chemistry from the University of Missouri-St. Louis in 2006 and 2008, respectively. Prior to that, Dr. Bongat was performing research at the University of the Philippines, where she had obtained her B. Sc. in Chemistry. For the past 6 years, she has been deeply involved in synthesizing biologically relevant carbohydrates and has found a deep and abiding love for the field. With this opportunity to train with a highly esteemed Carbohydrate chemist, Dr. Bongat anticipates productive days ahead.
|NIDA-IRP||Medicinal Chemistry Sectionfirstname.lastname@example.org||443-740-2887||Addiction/Neuroscience|
Our research effort is focused on the design and synthesis of novel ligands to study the function of selected CNS receptors and monoamine transporters. Highly selective compounds are designed for characterization of structure-activity relationships at these molecular targets. In addition, specific tools are synthesized such as irreversible, radiolabeled and/or fluorescent ligands for receptor topological mapping studies and the elucidation of pharmacological function. Our primary focus is toward elucidating mechanisms underlying addiction through the design, synthesis and pharmacological evaluation of novel dopamine uptake inhibitors and dopamine receptor subtype-selective ligands. In addition, we are synthesizing novel allosteric modulators of the mGluR5 receptor and the serotonin transporter.
|NHLBI||9800 Medical Center Dr Rm email@example.com||301-217-5759||Organic/Medicinal/Synthetic Chemistry|
I received my PhD form UPenn in ’06 doing work in the synthesis of self-assembling dendritic dipeptides. I spent some time as a postdoc in NICHD working on synthetic carbohydrate vaccines and am now currently a postodoc at the IPDC (NHLBI) working on the synthesis of novel imaging probes for targeting receptors, cells and tissues, and for preclinical in vivo evaluations. My areas of scientific interest lie in the application of synthetic organic/medicinal chemistry towards the treatment of viral diseases and bacterial infection.
|NIDDK||Laboratory of Bio Organic Chemistryfirstname.lastname@example.org||3014510169||Medicinal Chemistry|
I did my M.Sc form Indian Institute of Technology and PhD from Indian association for the cultivation of science. After finishing my 1st post doc at Kent State Univeristy I am doing my 2nd post doc at NIDDk, NIH, LBC, under the supervision of Dr. Kenneth A. Jacobson
|NIDDK||LBC / 8ARmB1A26email@example.com||301-402-3746||Nanotechnology|
Athena is a pharmacologist working in the area of nanotechnology. She is using PAMAM dendrimers as a method of drug delivery for GPCRs. SHe will also be testing the toxicity of different nanoparticles.
|NHGRI||NCGC 2053Efirstname.lastname@example.org||301-217-5729||Medicinal Chemistry|
Obtained both BS and MS from George Mason University. Worked for Merck West Point for ~2 years before joining the NCGC. Have applied a variety of synthetic methods to make biologically active molecules. Starting doctoral studies at Johns Hopkins in the summer of 2009.
|NIDDK||Bldg 8, Rm 1A23email@example.com||301-451-1093||Organic Chemistry|
Postdoctoral Fellow in Dr. Dan Appella's Lab in the NIDDK. Graduated from Univ. of Delaware Spring 2007 from Dr. Joel P. Schneider's lab after working with self-assembling beta-hairpin peptides.
|NCGC||9800 Medical Center Drivefirstname.lastname@example.org||301-217-5733||Medicinal chemistry, Pharmacology|
Christopher Austin is Director of the NIH Chemical Genomics Center (NCGC) and Senior Advisor to the Director for Translational Research at NHGRI. The NCGC is an ultrahigh-throughput screening, informatics, and chemistry center that develops novel compounds as probes of biology and starting points for development of new drugs for rare and neglected diseases, profiles small molecule libraries for biological activity, and develops new paradigms to increase the efficiency and genome-wide reach of assay, screening, chemistry, and informatics technologies. Dr. Austin received his A.B. from Princeton and M.D. from Harvard, trained in neuroscience and genetics, and came to NIH in 2002 from Merck.
I'm helping to create the Chemistry SIG site and will remove myself once this is up and running.
Colin M. Wilson has been a post-baccalaureate chemist at the Imaging Probe Development Center since its inception in late 2006. He is a graduate of the University of Delaware honors program. Under the direction of Dr. Gary Griffiths, the IPDC synthesizes known and novel imaging probes for the NIH intramural community. Colin is actively involved in projects ranging from the radiolabeling of small molecules to the synthesis of nanoparticle contrast agents.
|George Washington University||Department of Chemistry; Corcoran email@example.com||202-994-8405||Medicinal Chemistry|
Dr. Cynthia Dowd has a BA in Chemistry from the University of Virginia (1993) and a PhD in Medicinal Chemistry from Virginia Commonwealth University (1999). After a postdoc at the University of Pennsylvania, Dr. Dowd worked on the design and synthesis of antitubercular drugs at NIAID/NIH. In 2007, she joined the Chemistry Department faculty at George Washington University where her research focuses on anti-infective drug design.
I am a radiochemist specializing in radiolabeling of compounds with fluorine-18 for use in positron emission tomography.
|NIDDK||Laboratory of Bioorganic Chemistry, 8/1A21firstname.lastname@example.org||301-451-1052||Organic Chemistry, Nucleic Acids, DNA detection|
|NIH/NIDDK||Building 8, B1A25email@example.com||301-435-6791||Carbohydrate Chemistry|
Received Ph.D. in Organic Chemistry from American University, Washington, DC in 2006 under the guidance of Dr. Olivier Marcq and currently pursuing a post-doctoral fellowship in the lab of Dr. Paul Kovac, Section of Carbohydrates at NIDDK.
|NCI|| FCRF firstname.lastname@example.org||301-846-5995||Medicinal Chemistry|
Technical Laboratory Manager
Laboratory of Medicinal Chemistry
|NCI-Frederick||Bldg 562, Room email@example.com||301-846-6579||Natural Products|
I'm a postdoc in the Natural Products Group of the Molecular Targets Development Program.
|The George Washington University||Corcoran firstname.lastname@example.org||202-994-9268||Medicinal Chemistry|
After working for seven years as a research engineer for the DuPont Co. and then, 20 years of being a stay-at-home mother, I am returning to school to obtain a PhD in Organic Chemistry under Dr. Cynthia Dowd at the George Washington University.
|NHLBI||IPDCemail@example.com||301 217 5770||imaging and targeting|
I work on applied translational bioorganic chemistry directed to the localization and molecular imaging of biological and disease targets. Such agents run the range from intracellular imaging through clinical imaging and can use almost any type of detection modality including fluorescent, magnetic resonance and radiological. I seek to apply chemical expertise, knowledge and support in synthetic and bioorganic chemistry for the benefit of collaborating bioscientists. I have a PhD in synthetic organic chemistry and 20+ years working in translational research, molecular imaging, product development and disease-specific targeting and treatment.
German Cavelier, Ph.D.
Dr. Cavelier is the Chief of the Neurotechnology Program at the Division of Neurosciences in the National Institute of Mental Health. Previously, he was a Senior Research Scientist at the Department of Electrical Engineering and the Genome Center, Columbia University where he studied Genetic Regulatory Networks. Dr. Cavelier was a Professor of Electrical and Bioengineering and Vice-Dean for Research, School of Engineering, Universidad de los Andes, Bogota, Colombia where he created a Bioengineering Program. More recently, Dr. Cavelier obtained a Ph.D. in Molecular Biophysics at The Johns Hopkins University where his work centered on Computational Molecular Mechanics and Quantum Chemistry Analysis of Enzymatic Mechanisms.
|NIDDK||LBC/Bldg. 8 Rm. B2-A05firstname.lastname@example.org||301-402-7139||Chemical Biology|
|LDRR/CC||Bldg 10 Rm 1N306email@example.com||301-451-5166||MRI Contrast Agents|
Design, synthesis, in-vitro evaluation including T1/T2 NMRD profiles (relaxation data), and in-vivo imaging of MRI contrast agents.
|NIDDK||LBC, Bldg. 8A, Rm. B1Afirstname.lastname@example.org||301-435-1935||Medicinal Chemistry|
I came from Asubio Pharma Co., Ltd. (Japan) on August 2008.
I'm a medicinal chemist, and especially interested in structure-based drug design (SBDD). GPCR is a most challenging theme for SBDD, so I'm here (Dr. Jacobson's lab) for 1.5 year sabbatical.
|NIDA||Laboratory of Medicinal Chemistry/FL 4Nemail@example.com||301-435-1922||Organic, medicinal, synthetic chemistry|
|NINDS||Building 35, 3B 213 ||firstname.lastname@example.org||435-2114|
I completed my PhD in Biochemistry from Wisconsin-Madison. I worked with Ron Raines in Madison developing chemoselective bioconjugation methods, and characterizing the stability of bioconjugation linkages. I am now a postdoc at NINDS learning ion channel biophysics, and am planning to use chemical biology-based methods to answer questions in this field.
|NIDDK||Building 8, Room 1A04email@example.com||301-435-9260||Natural Products|
I am a graduate student in Carole Bewley's lab during my thesis research in collaboration with Georgetown University
|NIDA||Drug design and synthesis firstname.lastname@example.org||301-435-1912||Organic/Medicinal/Synthetic Chemistry|
|NIGMS||PPBC/Building 45, Room 2As.43Aemail@example.com||301-594-3827||Organic chemistry, natural products, chemical biology|
I'm a former academic (most recently, Purdue University) and joined NIGMS in 1996. I'm a program director responsible for grants in organic, natural products, and high-throughput chemistry, including the Chemical Methodologies and Library Development (CMLD) Centers. I'm also with the Molecular Libraries Roadmap program. I have a special interest in mentoring of young chemists and chemical biologists.
|NCI Frederick||Medicinal Chemistry firstname.lastname@example.org||301-846-5905||Medicinal Chemistry|
I received my PhD in Natural products/synthetic chemistry with Richard Moore at the U. of Hawaii and did post doc work with Bert Fraser-Reid at Duke University before joining the NCI where I have been ever since. I am a senior scientist/investigator in Medicinal Chemistry/carbohydrate chemistry/nanotechnology and am interested in the role of tumor-associated carbohydrates as they relate to tumor progression, metastasis and immunology.
I earned my B.S. in chemistry from Wittenberg University in Springfield, OH, and my M.S. from the University of Virginia. I worked for 2 years at Merck & Co. in Rahway, NJ before starting here at the NCGC as a chemist in September 2008.
|NIDA & NIAAA||5625 Fishers Lane, Rm. 4N03email@example.com||301-496-1856||Medicinal Chemistry|
Kenner Rice is Chief of the Chemical Biology Research Branch, National Institute on Drug Abuse. His research is medicinal chemistry based and focused on the elucidation of the structure and function of neurotransmitter systems in the central nervous system, and the development of medications for the treatment and prevention of drug abuse. He is the recipient of numerous research awards. In 2007, he received the E. E. Smissman Award of the American Chemical Society Division of Medicinal Chemistry and was inducted into the Division’s Medicinal Chemistry Hall of Fame as one of only 32 living members.
|NIDDK||LBC, Bldg. 8A, Rm. B1Afirstname.lastname@example.org||301-496-9024||Medicinal Chemistry|
Dr. Kenneth A. Jacobson is Acting Chief, Laboratory of Bioorganic Chemistry and Chief,
Molecular Recognition Section, NIDDK, NIH in Bethesda, Maryland. He is a medicinal chemist with interests in the structure and pharmacology of G protein-coupled receptors, in particular adenosine and nucleotide receptors. Ph.D. in Chemistry at the University of California, San Diego (1981), Bantrell Fellow at Weizmann Institute of Science. Awarded "Highly Cited Researcher" in Pharmacology and Toxicology, 2003 Hillebrand Prize of the Chemical Society of Washington, and 2009 Pharmacia-ASPET Award in Experimental Therapeutics. Dr. Jacobson has served as Chair of the Medicinal Chemistry Division of the ACS.
|NCI||Laboratory of Cell Biology / 37, email@example.com||301.435.6309||Pharmacology|
|NCI||Laboratory of Comparative Carcinogenesisfirstname.lastname@example.org||301-846-1467||Organic Chemistry|
After, I received my B.A. and Ph.D. degrees from Oberlin College (1961, chemistry) and the University of New Hampshire (1965, organic chemistry), respectively, I held research positions at the Chicago Medical School and the University of Nebraska College of Medicine before coming to the National Cancer Institute (NCI) in 1971. My colleagues and I, in the NCI's Chemistry Section, Laboratory of Comparative Carcinogenesis, are intensively studying the chemistry and pharmacology of the diazeniumdiolates as nitric oxide sources for biomedical applications.
|NIDA||Drug Design and Synthesis/Chemical Biology Research Branchemail@example.com||3014351921||Organic Chemistry|
opioid synthesis/medicinal chemistry
Bsc/PhD from the University of Sydney, specializing in bioinorganic chemistry and metal-based therapeutics. Now in LCB working on drug transporters in cancer multidrug resistance and drug development to overcome this phenomenon.
Dr. Michael Rogers, Director of the Pharmacology, Physiology, and Biological Chemistry, National Institute of General Medical Sciences, is a scientific administrator at NIH with expertise in medicinal chemistry, drug design, and drug discovery and development. He is one of four division directors at NIGMS and is responsible for the planning, organization, and administration of a large national program of grants and fellowships in the pharmacological, physiological, biochemical, and chemical sciences, including NIGMS’ only clinically relevant areas of anesthesiology, clinical pharmacology, trauma and burn injury, and wound healing and NIGMS’ intramural fellowship program, Pharmacology Research Associate program (PRAT). Major initiatives from his division are in the areas of chemical library development, metals in medicine, pharmacogenetics, and innovative centers in wound healing.
Dr. Fabian is a program director at the National Institute of General Medical Sciences (NIGMS) in the Division of Pharmacology, Physiology, and Biological Chemistry. He manages research applications and grants in the areas of bioorganic and medicinal chemistry. Prior to joining NIGMS, he was with Ambit Biosciences, where as the founding scientist. He earned a B.S. in chemistry from the University of Nebraska (Go Big Red) and a Ph.D. in biophysical chemistry from the University of California, San Diego under the tutelage of Charles Perrin.
|NCI||FVC firstname.lastname@example.org||301-846-5794||Natural Products, Drug Discovery|
Paul Grothaus earned a Ph.D. from Purdue University in 1983, for the first enantiospecific total synthesis of a trichothecene mycotoxin, anguidine. Following a postdoc at the University of Washington, he joined the Plant Sciences Division of Monsanto in 1984 where he investigated the synthesis and structure activity relationships of natural products for agricultural applications. In 1988, he became the head of chemistry at Hawaii Biotech where he led drug discovery efforts based upon both terrestrial and marine natural product leads. In 2002, he joined the Medicinal Chemistry department of Celera Genomics, Inc. in South San Francisco where he became an Associate Director of Medicinal Chemistry in 2005. Research at Celera focused on development of protease and kinase inhibitors and the development of activity-based probes for chemical proteomics studies. He joined the Natural Products Branch of the NCI in Frederick, MD. in 2007.
|NCI-Frederick||Laboratory of Medicinal Chemistryemail@example.com||301-846-5899||Medicinal Chemistry|
|NIDDK||Laboratory of Bioorganic Chemistry, 8/1A20firstname.lastname@example.org||301-496-8177||Bioorganic / Medicinal Chemistry, Molecular Recognition, Peptides / Proteins & Mimetics|
Dr. Sanjayan is a visiting scientist in the laboratory of Dr. Kenneth Jacobson, NIH. He is on sabbatical from the Division of Organic Chemistry, National Chemical Laboratory, Pune, India, (http://www.ncl-india.org/
), where he is a Scientist & Project Leader, leading a group of 10 PhD scholars, currently. He did his post-doctoral study (2001-2002) from Dyson Perrins Laboratory, University of Oxford, UK, on “carbohydrate-based synthetic oligomers” with Prof. George W. J. Fleet. His areas of interests are: Design, Synthesis and Bio-physical studies of Bio-inspired Molecules and their Oligomers (Peptides / Peptidomimetics).
Selected 3 recent Publications:
1. J. Am. Chem. Soc., 2008, 130, 17743.
2. Chem. Commun., 2008, 712.
3. Chem. Commun., 2008, 2541.
I have pursued my doctorial studies under the supervision of Prof. Jesper Wengel, University of Southern Denmark, where I worked on synthesizing modified nucleic acids and evaluated their potential application in the nucleic acid based therapeutics and diagnostics. Currently, I am working as postdoctorial visiting fellow in Dr. Kenneth Jacobson's lab.
|NIDDK||LBCemail@example.com||301-435-1937||Carbohydrate Synthetic Chemistry|
|NIDDK||LBMfirstname.lastname@example.org||301-451-7353||Molecular Modeling, Medicinal Chemistry, Biochemistry|
|NCI Frederick||Laboratory of Medicinal Chemistry email@example.com||301-846-5908||Medicinal Chemistry|
|NCI||Bldg 376 Boyles St., NCI-Frederickfirstname.lastname@example.org||301-846-5906||medicinal/bioorganic chemistry|
I received my Ph.D. in medicinal chemistry from the University of Washington (Seattle) and currently head the Bioorganic and Medicinal Chemistry Section within the Laboratory of Medicinal Chemistry. My research focuses on the application of peptide and peptide mimetic chemistries to areas of potential therapeutic interest to the NCI.
|SAIC/NCI Frederick||Laboratory of Synthetic Chemistryemail@example.com||301-846-5017||Organic/ Medicinal Chemistry|
After completing my Ph.D. from University of Delhi, India in 2007 I joined Laboratory of Synthetic Chemistry, SAIC/NCI as postdoc and now continuing as Research Scientist in the same laboratory.
|NIAID||TW 2, Rm firstname.lastname@example.org||301-480-3875||Medicinal Chemistry|
Hello. I am a recent graduate from UC Berkeley and am currently working in an immunology lab, studying the innate response to malarial infection in Malian patients.
|PET Radiopharmaceutical Science Section / NIMH||Building 10, Room B3C346email@example.com||301-451-3928 ||Medicinal Chemistry|
I joined the Section as a Radiochemist in 2008. I received my B.Sc. (Chemistry, 1990) and M.Sc. (Physical Chemistry, 1993) from Nan Kai University, China. I worked as a Research Associate and Lecturer at the Department of Chemical Engineering, Beijing Institute of Technology in China for three years before obtaining my Ph.D. (Organic Chemistry, 2001) from New Mexico State University, USA. I performed postdoctoral research on developing [18F]radiotracers for studying α4β2 nAChRs in the brain for three years at the National Institute on Drug Abuse (NIDA/NIH). Before joining NIMH, I spent five years working on developing drugs for CNS disorders in the Intramural Research Program at the PET section of NIDA/NIH, followed by two years as a Research Scientist developing opioid ligands within the Drug Design and Synthesis Section, Chemical Biology Research Branch. My current interests focus on producing radiotracers for PET studies, developing new radiosynthetic methods with modified automated apparatus and documentation of radiotracer production according to GMP requirements in support of IND applications.